Skye Bioscience (SKYE) Share-based Compensation (2015 - 2026)
Skye Bioscience (SKYE) posted quarterly Share-based Compensation of $1.5 million for Q1 2026, down 32.01% year-over-year from $2.2 million in Q1 2025, and up 124.34% quarter-over-quarter from -$6.1 million in Q4 2025.
Skye Bioscience (SKYE) Share-based Compensation (2015 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Share-based Compensation for 12 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 32.01% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at -$704920.0 (down 108.77% YoY), while the FY2024 annual figure was $8.3 million, up 742.27% from the prior year.
- Share-based Compensation improved to $1.5 million in Q1 2026 per SKYE's latest filing, from -$6.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.5 million in Q1 2024 and bottomed at -$6.1 million in Q4 2025.
- Historically, Share-based Compensation has averaged $672412.4 across 5 years, with a median of $592853.0 in 2023.
- Annual changes were most pronounced in 2024 — Share-based Compensation jumped 1783.42% — and 2025, when it sank 394.33%.
- Skye Bioscience's Share-based Compensation stood at $203186.0 in 2022, then soared by 191.78% to $592853.0 in 2023, then surged by 252.4% to $2.1 million in 2024, then tumbled by 394.33% to -$6.1 million in 2025, then jumped by 124.34% to $1.5 million in 2026.
- Business Quant data shows SKYE's Share-based Compensation at $1.5 million in Q1 2026, -$6.1 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | 1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.50 Mn |
| Mar 31, 2026 | 1.50 Mn |
| Dec 31, 2025 | -6.15 Mn |
| Dec 31, 2025 | -6.15 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 1.92 Mn |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Mar 31, 2024 | 2.48 Mn |
| Mar 31, 2024 | 2.48 Mn |
| Dec 31, 2023 | 592,853.00 |
| Dec 31, 2023 | 592,853.00 |